Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NALIRIFOX in Advanced Small Intestine and Appendiceal Cancers
NCT07060014Phase 1Recruiting
- Sponsor
- Houston Methodist Research Institute
- Start
- Sep 2026
- Primary completion
- Sep 2028
- Modality
- Lipid-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of nanoliposomal irinotecan, fluorouracil, folinic acid and oxaliplatin in small intestine cancer and appendiceal cancer (2 arms), sponsored by Houston Methodist Research Institute. Primary endpoint: Treatment-Related Adverse Events at 12 months. Started Sep 2026; status: recruiting.
02
Drugs
nanoliposomal irinotecanfluorouracilfolinic acidoxaliplatin
03
Conditions
small intestine cancerappendiceal cancer
Beyond the preview
Go deeper on NCT07060014.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07060014.